# US 2021/0275482 A1 · Compounds for the treatment of obesity and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275482 A1
- Document ID: US20210275482A1
- Status: Published application
- Kind: A1
- Application number: 17/326,944
- Filed: 2021-05-21
- Published: 2021-09-09
- Earliest claimed: 2012-09-27
- Assignees: Children's Medical Center Corporation; The General Hospital Corporation
- Applicants: The Children's Medical Center Corporation; The General Hospital Corporation
- Inventors: Umut Ozcan; Joseph Majzoub; Ralph Mazitschek
- Web page: https://patentgrep.com/patent/US20210275482A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/195: having an amino group
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A pharmaceutical dosage formulation for oral administration of sustained or controlled release of an active agent to a pre-obese, obese, or morbidly obese human, the active agent consisting of celastrol
wherein the celastrol is present in an amount between 0.005 mg and 1 mg per kg of body weight of the human, which is effective to induce weight loss, reduce the body fat, reduce food intake, improve glucose homeostasis, or combinations thereof, in the pre-obese, obese, or morbidly obese human in the absence of systemic toxicity,
in a pharmaceutically acceptable oral dosage formulation selected from the group consisting of tablets, capsules, solutions, suspensions, syrups, granules, beads, powders and lozenges.

### Claim 24 (depends on 23)

The pharmaceutical dosage formulation of claim 23 in a pharmaceutically acceptable oral dosage formulation selected from the group consisting of tablets, capsules, granules, beads, powders and lozenges.

### Claim 25 (depends on 23)

The pharmaceutical dosage formulation of claim 23, wherein the celastrol is present in a dosage between 0.005 mg and 0.1 mg per kg of body weight of the human.

### Claim 26 (depends on 23)

The pharmaceutical dosage formulation of claim 23, wherein the dosage formulation is a capsule or tablet, wherein the celastrol is in an amount for oral administration once or twice daily.

### Claim 27 (depends on 23)

The pharmaceutical dosage formulation of claim 23, wherein the celastrol is in a dosage for oral administration once daily.

### Claim 28 (depends on 23)

A method of inducing weight loss, reducing the body fat, reducing food intake, improving glucose homeostasis, or combinations thereof, in a pre-obese, obese, or morbidly obese human, comprising orally administering to the human an effective amount of the pharmaceutical dosage formulation of claim 23.

### Claim 29 (depends on 28)

The method of claim 28, wherein the effective amount is effective to reduce the average daily food calorie intake by at least 15% in the pre-obese, obese, or morbidly obese human.

### Claim 30 (depends on 28)

The method of claim 28, wherein the effective amount is effective to decrease body fat in the pre-obese, obese, or morbidly obese human by at least 10%.

### Claim 31 (depends on 28)

The method of claim 28, wherein the effective amount is effective to decrease body fat in the pre-obese, obese, or morbidly obese human by at least 20%.

### Claim 32 (depends on 28)

The method of claim 28, wherein the effective amount is effective to decrease body mass in the pre-obese, obese, or morbidly obese human by at least 10%.

### Claim 33 (depends on 28)

The method of claim 28, wherein the effective amount is effective to decrease body mass in the pre-obese, obese, or morbidly obese human by at least 20%.

### Claim 34 (depends on 28)

The method of claim 28, wherein the effective amount is effective to reduce average fasting plasma blood glucose by at least 10%.

### Claim 35 (depends on 28)

The method of claim 28, wherein the effective amount is effective to lower blood glucose levels to less than about 180 mg/dL.

### Claim 36 (depends on 28)

The method of claim 28, wherein the celastrol is administered at a dosage between 0.005 mg and 0.1 mg per kg of body weight of the human.

### Claim 37 (depends on 28)

The method of claim 28, wherein the celastrol is administered once or twice daily.

### Claim 38 (depends on 28)

The method of claim 28, wherein the celastrol is administered once daily or less frequent.
